Postherpetic Neuralgia - Pipeline Review, H1 2015

Published: Apr, 2015 | Pages: 107 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Postherpetic Neuralgia - Pipeline Review, H1 2015

Summary 

Global Markets Direct's, 'Postherpetic Neuralgia - Pipeline Review, H1 2015', provides an overview of the Postherpetic Neuralgia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Postherpetic Neuralgia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Postherpetic Neuralgia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Postherpetic Neuralgia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Postherpetic Neuralgia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason To Buy 

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Postherpetic Neuralgia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Postherpetic Neuralgia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Postherpetic Neuralgia Overview 9
Therapeutics Development 10
Pipeline Products for Postherpetic Neuralgia - Overview 10
Pipeline Products for Postherpetic Neuralgia - Comparative Analysis 11
Postherpetic Neuralgia - Therapeutics under Development by Companies 12
Postherpetic Neuralgia - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Postherpetic Neuralgia - Products under Development by Companies 18
Postherpetic Neuralgia - Companies Involved in Therapeutics Development 20
Aestus Therapeutics, Inc. 20
Allergan, Inc. 21
Arcion Therapeutics, Inc. 22
Astellas Pharma Inc. 23
Daewoong Pharmaceutical Co., Ltd. 24
Daiichi Sankyo Company, Limited 25
Immune Pharmaceuticals, Ltd. 26
Intellipharmaceutics International Inc. 27
Merck & Co., Inc. 28
NeurAxon, Inc. 29
Nuvo Research Inc. 30
Pfizer Inc. 31
Phosphagenics Limited 32
Purdue Pharma L.P. 33
Relmada Therapeutics, Inc. 34
Scilex Pharmaceuticals, Inc. 35
Spinifex Pharmaceuticals Pty Limited 36
Teva Pharmaceutical Industries Limited 37
Winston Pharmaceuticals, Inc. 38
Postherpetic Neuralgia - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Target 41
Assessment by Mechanism of Action 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
(amitriptyline + ketamine hydrochloride) - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
(naltrexone hydrochloride+ clonidine hydrochloride) - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ASP-8477 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Atx08-001 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
bupivacaine hydrochloride - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
C-746 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CNV-2197944 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
DWP-05195 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
EMA-401 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Flexicaine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
FV-100 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
ketoprofen - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
lidocaine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
lidocaine hydrochloride - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
mepivacaine hydrochloride - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
mirogabalin - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
MK-8291 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
NXN-462 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
oxycodone ER - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
pregabalin CR - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
pregabalin ER - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
senrebotase - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
TV-45070 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
V-116517 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
zucapsaicin - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Postherpetic Neuralgia - Recent Pipeline Updates 83
Postherpetic Neuralgia - Dormant Projects 97
Postherpetic Neuralgia - Discontinued Products 99
Postherpetic Neuralgia - Product Development Milestones 100
Featured News & Press Releases 100
Apr 02, 2015: Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia 100
Feb 20, 2015: ContraVir Pharmaceuticals Provides Clinical Update on FV-100 100
Feb 19, 2015: Xenon Pharmaceuticals Partner Teva to Initiate Phase 2b Clinical Trial of TV-45070 in Post-Herpetic Neuralgia 101
Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin 101
Jan 07, 2015: ContraVir Pharmaceuticals Granted FDA Meeting to Discuss Proposal for Phase 3 Trial of FV-100 102
Dec 18, 2014: Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia 103
Aug 11, 2014: Scilex Pharmaceuticals Completes Trial Enrollment for Ztlido 103
Jul 14, 2014: SCILEX Pharmaceuticals Commences Dermal Safety Studies of Ztlido 104
May 19, 2014: Scilex Pharmaceuticals Initiates Pivotal Pharmacokinetic Study for Ztilido 104
Mar 24, 2014: Scilex Pharmaceuticals Announces Filing of Investigational New Drug Application for Ztilido 105
Appendix 106
Methodology 106
Coverage 106
Secondary Research 106
Primary Research 106
Expert Panel Validation 106
Contact Us 106
Disclaimer 107

List of Tables

Number of Products under Development for Postherpetic Neuralgia, H1 2015 10
Number of Products under Development for Postherpetic Neuralgia - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Comparative Analysis by Unknown Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Postherpetic Neuralgia - Pipeline by Aestus Therapeutics, Inc., H1 2015 20
Postherpetic Neuralgia - Pipeline by Allergan, Inc., H1 2015 21
Postherpetic Neuralgia - Pipeline by Arcion Therapeutics, Inc., H1 2015 22
Postherpetic Neuralgia - Pipeline by Astellas Pharma Inc., H1 2015 23
Postherpetic Neuralgia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 24
Postherpetic Neuralgia - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 25
Postherpetic Neuralgia - Pipeline by Immune Pharmaceuticals, Ltd., H1 2015 26
Postherpetic Neuralgia - Pipeline by Intellipharmaceutics International Inc., H1 2015 27
Postherpetic Neuralgia - Pipeline by Merck & Co., Inc., H1 2015 28
Postherpetic Neuralgia - Pipeline by NeurAxon, Inc., H1 2015 29
Postherpetic Neuralgia - Pipeline by Nuvo Research Inc., H1 2015 30
Postherpetic Neuralgia - Pipeline by Pfizer Inc., H1 2015 31
Postherpetic Neuralgia - Pipeline by Phosphagenics Limited, H1 2015 32
Postherpetic Neuralgia - Pipeline by Purdue Pharma L.P., H1 2015 33
Postherpetic Neuralgia - Pipeline by Relmada Therapeutics, Inc., H1 2015 34
Postherpetic Neuralgia - Pipeline by Scilex Pharmaceuticals, Inc., H1 2015 35
Postherpetic Neuralgia - Pipeline by Spinifex Pharmaceuticals Pty Limited, H1 2015 36
Postherpetic Neuralgia - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 37
Postherpetic Neuralgia - Pipeline by Winston Pharmaceuticals, Inc., H1 2015 38
Assessment by Monotherapy Products, H1 2015 39
Assessment by Combination Products, H1 2015 40
Number of Products by Stage and Target, H1 2015 42
Number of Products by Stage and Mechanism of Action, H1 2015 44
Number of Products by Stage and Route of Administration, H1 2015 46
Number of Products by Stage and Molecule Type, H1 2015 48
Postherpetic Neuralgia Therapeutics - Recent Pipeline Updates, H1 2015 83
Postherpetic Neuralgia - Dormant Projects, H1 2015 97
Postherpetic Neuralgia - Dormant Projects (Contd..1), H1 2015 98
Postherpetic Neuralgia - Discontinued Products, H1 2015 99